AdBio partners
VC Fund
Paris, France
AdBio partners is a European Life Sciences Venture Capital firm dedicated to seeding healthcare’s step forward.We work with leading research institutions and well-established technology transfer offices, with a strong network of scientific and medical partners, exploring new territories to source breakthrough medical discoveries and driveinventive Life Sciences start-ups to success.We embrace European Life Sciences’ dynamic of innovation. Europe harbors a vibrant environment for medical and scientific investigation, with some of the most leading-edge academic and research centers. AdBio partners seizes the opportunity to highlight their undervalued research programs and assets and participate in structuring Europe’s biotechnology ecosystem.
- Total investments:
- 32
- Last investment:
- Lead investor:
- 41%
- Fund size:
- $116M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries AdBio partners invests in
Stages AdBio partners invests in
Countries AdBio partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 6 contacts → | |||
Round size
- Seed
- $2.2M–$18M
- Series A
- $18M–$37M
- Venture - Series Unknown
- $2.2M–$16M
Investment Focus
Industry
- Biotechnology 17 (53%)
- Health Care 6 (19%)
- Pharmaceutical 4 (13%)
- Medical 3 (9%)
- Biopharma 2 (6%)
Stage
- Seed 14 (44%)
- Series A 4 (13%)
- Venture - Series Unknown 4 (13%)
- Series B 2 (6%)
- Series C 1 (3%)
Country
- France 11 (34%)
- Spain 3 (9%)
- Belgium 3 (9%)
- Denmark 1 (3%)
- Switzerland 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Alain Huriez
President & General Partner
|
President & General Partner | Total investments: 8 | Find email | |
Arnaud Foussat
Operating Partner
|
Operating Partner | Total investments: 0 | Find email | |
Matthieu Coutet
Managing Partner
|
Managing Partner | Total investments: 8 | Find email | |
Francesc Dosrius
Junior Analyst
|
Junior Analyst | Total investments: 0 | Find email | |
Jeremie Mariau
Operating Partner
|
Operating Partner | Total investments: 0 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Orikine Bio is a pioneer biotech company in the field of tailored cytokines with unmatched biological properties for the treatment of immune-mediated disorders. | $3.2M / Seed / Feb 02, 2026 | ||
| ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing antisense RNA treatments against genetic diseases. Our team has a strong background on drug discovery and microRNAs involvement in neuromuscular diseases. We are supported by world-renowned scientific and clinical advisors that will facilitate the successfuldevelopment of our products. | $40.6M / Series B / Sep 17, 2025 | ||
| Integra Therapeutics is a developer of next generation of gene editing tools to cure diseases. | $3.2M / Seed / Sep 17, 2025 | ||
| Integra Therapeutics is a developer of next generation of gene editing tools to cure diseases. | $12.6M / Seed / Sep 08, 2025 | ||
| EvlaBio is a biotech company focused on the development of drug programs that address significant unmet medical needs. The company's pipeline includes robust scientific antibody programs for the treatment of hepatocellular carcinoma (Phase 1 ready) and chronic kidney disease with left ventricular hypertrophy (pre-clinical). | $24.6M / Seed / Jul 07, 2025 | ||
| Cephagenix focuses on identifying and developing new, effective migraine therapies. | $9.3M / Seed / Jan 16, 2025 | ||
| Tenpoint Therapeutics is a biotechnology company pursuing vision-restoring engineered cell-based therapeutics. | Venture - Series Unknown / Dec 11, 2024 | ||
| Augustine Therapeutics company is a two drug discovery programs to identify novel generations of selective HDAC6 inhibitors for the treatment of axonopathies such as Charcot Marie Tooth disease. These new compounds have the potential to protect from nerve degeneration and promote peripheral myelin and axon repair. | $18.2M / Series A / Jun 26, 2024 | ||
| AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases. | $100.8M / Series C / Oct 11, 2023 | ||
| Orikine Bio is a pioneer biotech company in the field of tailored cytokines with unmatched biological properties for the treatment of immune-mediated disorders. | $6.2M / Seed / Jul 18, 2023 | ||
| See all 32 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does AdBio partners invest in?
AdBio partners invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Seed and Series A stage. Most of the 32 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is AdBio partners's check size?
AdBio partners typically joins rounds of $2.2M–$18M at Seed, $18M–$37M at Series A and $2.2M–$16M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds AdBio partners participates in.
How do I contact AdBio partners?
Public channels for AdBio partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at AdBio partners?
The team at AdBio partners includes Alain Huriez (President & General Partner), Arnaud Foussat (Operating Partner) and Matthieu Coutet (Managing Partner), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
